Ad5-hGCC-PADRE

AXP000164.1 · Cancer vaccine

Platform
adenovirus (Ad5, guanylyl cyclase C)
Targets
GUCY2C
Originator
Thomas Jefferson University
Sponsor
Thomas Jefferson University

Names

NameTypeSource
Ad5-hGCC-PADREpreferred name, codecurator, ncit
Adenovirus 5-Human Guanylyl Cyclase C-PADRE Vaccine ambiguoussynonymncit

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
non replicating
Modifications
non-replicating adenoviral vector encoding guanylyl cyclase C fused to the PADRE helper epitope
Transgenes
GUCY2C
Source
evidence

Cross-references

NCI Thesaurus
C112005

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT01972737Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon CancerCompletedPhase 12013-102014-06-0310Colon Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 31010434Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.Journal for immunotherapy of cancer2019cited by trial NCT01972737
PMID 27716119A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients.BMC cancer2016cited by trial NCT01972737

Notes

Adenovirus type 5 expressing human guanylyl cyclase C fused to the universal helper T-cell epitope PADRE; phase 1 in gastrointestinal cancers. An Ad5.F35 chimeric version has also been studied; vector details not verified beyond the NCIt record.

How to cite

Ad5-hGCC-PADRE (AXP000164.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000164.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.